BCAX
Bicara Therapeutics Inc.18.15
-0.21-1.14%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Key Stats
Market Cap
994.29MP/E (TTM)
3.37Basic EPS (TTM)
5.38Dividend Yield
0%Recent Filings
8-K
Phase 1b data advances dose selection
Bicara Therapeutics released preliminary Phase 1b data on December 6, 2025, showing 750mg ficerafusp alfa weekly plus pembrolizumab delivered a 57% confirmed ORR and 10% CR rate in first-line HPV-negative R/M HNSCC, with a well-tolerated profile matching the 1500mg dose. Higher 1500mg dosing boosted TGF-β inhibition, deeper responses (82% median depth vs 63%), and immune activation. Optimal dose for pivotal FORTIFI-HN01 declares Q1 2026. Data derisks interim ORR analysis.
10-Q
Q3 FY2025 results
Bicara Therapeutics posted Q3 FY2025 net loss of $36.3M, up 108% y/y from $17.5M, driven by R&D expenses doubling to $33.0M on clinical operations ($14.0M, +161% y/y) and manufacturing ($11.0M, +54% y/y) for the pivotal FORTIFI-HN01 Phase 2/3 trial. Operating loss widened to $40.7M from $20.6M y/y, offset by $4.4M interest income. Cash and equivalents fell to $171.7M with $236.1M invested in Treasuries, yielding $407.6M total liquidity into H1 2029. No debt. Patent inventorship litigation ongoing. Business hinges on ficerafusp alfa success.
8-K
FDA Breakthrough for ficerafusp
Bicara Therapeutics secured FDA Breakthrough Therapy Designation for ficerafusp alfa plus pembrolizumab in first-line HPV-negative R/M HNSCC, validating its clinical promise. Cash stands at $407.6 million as of September 30, 2025, funding operations into H1 2029 despite Q3 net loss of $36.3 million. Phase 1b data hits ESMO Asia 2025. Cash burn accelerates.
10-Q
Q2 FY2025 results
Bicara Therapeutics posted a Q2 net loss of $27.4 million, up 61% y/y from $17.0 million, driven by R&D expenses climbing 57% to $24.8 million on clinical trial ramp-up and headcount growth, while G&A rose 85% to $7.2 million amid public company costs. YTD through June 30, 2025, losses widened to $64.2 million from $29.6 million, with R&D surging 112% to $59.1 million fueled by manufacturing and FORTIFI-HN01 Phase 2/3 trial enrollment. Cash burned $53.1 million in H1, leaving $436.6 million at quarter-end, sufficient into mid-2029 per management. No debt; free cash flow not disclosed in the 10-Q. Ongoing Y-Trap patent litigation poses inventorship risks to ficerafusp alfa. Clinical delays could stall pipeline progress.
8-K
Bicara Q2 results and trial updates
Bicara Therapeutics reported Q2 2025 net loss of $27.4 million, up from $17.0 million last year, driven by ramped-up R&D spending on ficerafusp alfa trials. Updated Phase 1/1b data at ASCO 2025 showed 54% ORR and 21.7-month median DOR in HPV-negative HNSCC patients. Cash stands at $436.6 million, funding operations into H1 2029. Additional data expected Q4 2025 to Q1 2026. Clinical progress fuels pivotal trial momentum.
ATRA
Atara Biotherapeutics, Inc.
17.58-0.37
AURA
Aura Biosciences, Inc.
6.18-0.15
BCAB
BioAtla, Inc.
0.76-0.01
BCTX
BriaCell Therapeutics Corp.
8.70-0.28
BCYC
Bicycle Therapeutics plc
7.31-0.02
BOLT
Bolt Biotherapeutics, Inc.
5.45+0.06
CDTX
Cidara Therapeutics, Inc.
220.05-0.05
CNTX
Context Therapeutics Inc.
1.10-0.03
ELTX
Elicio Therapeutics, Inc.
8.15-0.37
TARA
Protara Therapeutics, Inc.
5.42-0.08